CorMedix, Inc. (CRMD) has surged 0.53% and closed its last trading session at $0.53.
Insider Trading is buying and selling of a security by a person who has access to material information related to a security that is not available to general public. It can be both illegal and legal. For instance, insider trading is illicit when the trader has special information, which is not available to other shareholders.
“CEO at CorMedix, Inc., Baluch Khoso on 2017-12-12 Buy 104166 shares of the company at a price of $0.48. Similarly, the company’s Exec VP of Tech Operations ARMSTRONG JR. JOHN L. on 2017-12-12 Buy 20833 shares of the company at a price of $0.48.”
Now we will discuss the financial strength of CorMedix, Inc.. The company’s average Piotroski F-Score: 4 during the last 7 years. Its mean Altman Z-Score: -15.55 during the last 7 years, while average Beneish M-Score: -6.05 during the last 7 years.
Revenue growth shows increase or decrease in sales over time. It is used to find out how fast a business is expanding. The average revenue per share growth rate of CorMedix, Inc. during the past 12 months was 166.7 percent.
EBITDA margin is an indicator of a company’s operating profitability as a percentage of its overall revenue. It is equal to earnings before interest, tax, depreciation and amortization (EBITDA) divided by overall revenue. CorMedix, Inc.’s average EBITDA per Share Growth Rate was 0 percent during the past 12 months.
The Relative Strength Index (RSI), developed by J. Welles Wilder, is a momentum oscillator that calculates the speed and change of price movements. The RSI oscillates between zero and 100. Relative Strength Index (RSI-14) for CorMedix, Inc. (CRMD) is at 45.52.
Analysts look for public financial statements, listen in on conference calls and talk to managers and customers of a company in order to reach an opinion and communicate the value of a stock. Ultimately, through all this investigation into the company’s performance the analyst decides if their stock is a “buy,” sell” or hold.”
CorMedix, Inc. was covered by a number of analysts recently, 0 rated the stock as Buy, 1 rated Outperform, 1 rated Hold, 0 gave an Underperform and 0 rated sell.
The market capitalization of CorMedix, Inc. is at $36.6 Million. The company has an Average True Range (ATR) value of 0.04, while a Beta Value of 0.34. The YTD performance of the stock stands at 5.64 Percent. The Weekly and Monthly Volatility of the stock are 6.50% percent and 6.81% percent, respectively.
The SMA20 for the stock is at -4.48 percent, SMA50 stands at -3.84 percent, while SMA200 is -8.27 Percent.